Dutch Sub Study: Controlled Rosuvastatin Multinational Study in Heart Failure (CORONA). PET Sub Study

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00228514
First received: September 27, 2005
Last updated: November 11, 2010
Last verified: November 2010
  Purpose

At one site, patients participating in the Corona main study are asked to participate in the PET-substudy. Before and 6 months after study medication is started a Positron Emission Tomography (PET-scan) is performed to study the effect of rosuvastatin in Chronic Heart Failure on myocardial perfusion (reserve)


Condition Intervention Phase
Rosuvastatin
Heart Failure
Positron Emission Tomography (PET)
Drug: Rosuvastatin
Procedure: Positron emission tomography
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: Sub Study: Controlled Rosuvastatin Multinational Study in Heart Failure (CORONA) PET Sub Study

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • To study the effect of rosuvastatin in Chronic Heart Failure on myocardial perfusion (reserve). Before and 6 months after study medication is started a Positron Emission Tomography (PET-scan) is performed.

Secondary Outcome Measures:
  • To study the effect of rosuvastatin in Chronic Heart Failure on mismatch. Before and 6 months after study medication is started a Positron Emission Tomography (PET-scan) is performed.

Estimated Enrollment: 40
Study Start Date: February 2004
Study Completion Date: July 2007
Intervention Details:
    Drug: Rosuvastatin
    Other Name: Crestor
    Procedure: Positron emission tomography
  Eligibility

Ages Eligible for Study:   60 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients fulfilling the in and exclusion criteria of the CORONA study and separate informed consent for participation in the sub study.

Exclusion Criteria:

  • See above
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00228514

Locations
Netherlands
Research Site
Groningen, Netherlands
Sponsors and Collaborators
AstraZeneca
Investigators
Study Director: AstraZeneca CV Medical Department AstraZeneca BV
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00228514     History of Changes
Other Study ID Numbers: 4522IL/0098 Dutch SubStudy, D3562C00098
Study First Received: September 27, 2005
Last Updated: November 11, 2010
Health Authority: Netherlands: Medical Ethics Review Committee (METC)

Additional relevant MeSH terms:
Heart Failure
Cardiovascular Diseases
Heart Diseases
Rosuvastatin
Anticholesteremic Agents
Antimetabolites
Enzyme Inhibitors
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Hypolipidemic Agents
Lipid Regulating Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses

ClinicalTrials.gov processed this record on October 23, 2014